摘要
目的探讨阿柏西普联合曲安奈德治疗视网膜中央静脉阻塞继发黄斑水肿的效果。方法收集2019年10月至2021年6月在本院就诊的视网膜中央静脉阻塞继发黄斑水肿患者60例(60眼)。采用随机数字表法分组,即对照组、观察组,均30例(30眼)。对照组采用单纯0.05ml阿柏西普治疗,注射3次;观察组在对照组的基础上再予以曲安奈德治疗,20mg/0.5mL。分别于治疗前及治疗后1月、3月和6月观察患者视力、黄斑中心区厚度、眼压变化情况,进行统计学分析。结果治疗前,两组视力比较,P>0.05;治疗1月后观察组视力(0.35±0.11)logMAR显著低于对照组,P<0.05;治疗3月、6月后两组视力比较,P>0.05。与治疗前比较,两组患者治疗后1月、3月、6月视力均显著提升,P<0.05。治疗前,两组黄斑中心区厚度比较,P>0.05;治疗1月、3月、6月后观察组黄斑中心区厚度均显著低于对照组,P<0.05。与治疗前比较,两组患者治疗后1月、3月、6月黄斑中心区厚度均显著下降,P<0.05。治疗前,两组眼压比较,P>0.05;治疗1月、3月、6月后两组眼压比较,P>0.05。与治疗前比较,两组治疗后1月、3月、6月眼压无明显变化,P>0.05。但是治疗后1月较治疗前有所升高。两组不良反应发生率比较,χ^(2)=0.577,P>0.05。结论阿柏西普联合曲安奈德治疗视网膜中央静脉阻塞继发黄斑水肿效果理想,显著改善患者视力及黄斑中心区厚度,值得推广。
Objective To investigate the effect of aflibercept combined with triamcinolone acetonide in the treatment of macular edema secondary to central retinal vein occlusion.Methods A total of 60 patients(60 eyes)with macular edema secondary to central retinal vein occlusion who were treated in our hospital from October 2019 to June 2021 were collected.The random number table method was used to divide into groups,namely the control group and the observation group,with 30 cases(30 eyes).The control group was treated with 0.05mL aflibercept alone and injected 3 times;the observation group was additionally treated with triamcinolone acetonide,20mg/0.5mL,on the basis of the control group.The changes of visual acuity,central macular thickness and intraocular pressure were observed before treatment and at 1 month,3 months and 6 months after treatment,and statistical analysis was performed.Results Before treatment,the visual acuity of the two groups compared,P>0.05.After 1 month,the visual acuity of the observation group(0.35±0.11)logMAR was significantly lower than that of the control group,P<0.05.After 3 months and 6 months of treatment,the visual acuity of the two groups compared,P>0.05.Compared with before treatment,the visual acuity of the two groups improved significantly at 1 month,3 months and 6 months after treatment,P<0.05.Before treatment,the thickness of the central macular area of the two groups compared,P>0.05.After 1 month,3 months,and 6 months of treatment,the thickness of the central macular area of the observation group was significantly lower than that of the control group,P<0.05.Compared with before treatment,the thickness of central macular area in the two groups decreased significantly at 1 month,3 months,and 6 months after treatment,P<0.05.Before treatment,the comparison of intraocular pressure between the two groups,P>0.05,after 1 month,3 months,and 6 months of treatment,the comparison of intraocular pressure between the two groups,P>0.05.Compared with before treatment,there was no significant change i
作者
张明华
闫俊茹
魏菁
ZHANG Ming-hua;YAN Jun-ru;WEI Jing(Department of Ophthalmology,the First Affiliated Hospital of Henan University of Science and Technology,Luoyang 471000,Henan Province,China;Department of Ophthalmology,Zhumadian Eye Hospital,Zhumadian 46300,Henan Province,China)
出处
《罕少疾病杂志》
2022年第8期19-20,25,共3页
Journal of Rare and Uncommon Diseases
关键词
视网膜中央静脉阻塞
黄斑水肿
阿柏西普
曲安奈德
视力
黄斑中心区厚度
眼压
Central Retinal Vein Occlusion
Macular Edema
Aflibercept
Triamcinolone Acetonide
Visual Acuity
Central Macular Thickness
Intraocular Pressure
